Solid Biosciences (NASDAQ:SLDB - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Wednesday, May 21st. Analysts expect Solid Biosciences to post earnings of ($0.53) per share for the quarter.
Solid Biosciences Price Performance
Solid Biosciences stock opened at $2.79 on Wednesday. The business has a 50 day simple moving average of $3.68 and a 200-day simple moving average of $4.27. Solid Biosciences has a 12 month low of $2.45 and a 12 month high of $10.46. The stock has a market capitalization of $216.23 million, a PE ratio of -0.92 and a beta of 2.32.
Analysts Set New Price Targets
Several analysts have recently commented on SLDB shares. JPMorgan Chase & Co. reduced their price target on Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating for the company in a report on Thursday, March 13th. Chardan Capital restated a "buy" rating and set a $16.00 target price on shares of Solid Biosciences in a research report on Friday, March 7th. Finally, HC Wainwright upped their price target on shares of Solid Biosciences from $16.00 to $20.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Eight investment analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $15.67.
Get Our Latest Stock Report on Solid Biosciences
About Solid Biosciences
(
Get Free Report)
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Solid Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.
While Solid Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
